## Edgar Filing: Raptor Pharmaceutical Corp - Form 4

Raptor Pharm Form 4 April 19, 201	naceutical Corr	þ									
FORM 4 UNITED STATES SECUR Wash Check this box if no longer subject to Section 16. Form 4 or Form 5 eblications				ITIES AND EXCHANGE COMMISSION hington, D.C. 20549 GES IN BENEFICIAL OWNERSHIP OF SECURITIES 6(a) of the Securities Exchange Act of 1934,				OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5			
obligation may cont <i>See</i> Instru 1(b). (Print or Type F	ns Section 1'	7(a) of the		ility Hold	ing Com	pany	Act o	f 1935 or Sectio	n		
LAPOINTE ANTHONY GREGG Symbol			2. Issuer Name <b>and</b> Ticker or Trading ymbol aptor Pharmaceutical Corp [RPTP] Date of Earliest Transaction Aonth/Day/Year) 4/15/2016				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Officer (give title 10% Owner Officer (give title 0ther (specify below)				
(Month/Da											
				ndment, Date Original hth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NOVATO, ( (City)	CA 94949 (State)	(Zip)	Table	- I - Non-D	erivative S	Securi	ties A c	Person	More than One Re		
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ar) Executi any		TransactionAcquired (A) or Code Disposed of (D) Benefic (Instr. 8) (Instr. 3, 4 and 5) Owned Followi (A) Transac		5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-			
Common Stock	04/15/2016			А	2,092 (1) (2)	A	\$0	2,092	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. I Der Sec (In:
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock options (right to buy)	\$ 5.22	04/15/2016		А	7,915	(2)	04/15/2026	Common Stock	7,915	

## Edgar Filing: Raptor Pharmaceutical Corp - Form 4

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
LAPOINTE ANTHONY GREGG C/O RAPTOR PHARMACEUTICAL CORP 7 HAMILTON LANDING, SUITE 100 NOVATO, CA 94949	Х					
Signatures						
/s/ Sally Brammell, Raptor Pharmaceutical Co Attorney-in-Fact	rp.,		04/1	9/2016		
<u>**Signature of Reporting Person</u>			]	Date		

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Restricted Stock Units ("RSUs"). The Reporting Person is entitled to one (1) share of common stock for each one (1) RSU upon the (1) vesting thereof.
- (2) Stock options and RSUs vest fully immediately prior to the Company's 2016 Annual Meeting of Stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.